MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 142 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.87 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,085,729 | +46.2% | 171,773 | +131.2% | 0.00% | +50.0% |
| Q2 2023 | $17,161,683 | -52.1% | 74,293 | -49.7% | 0.00% | -50.0% |
| Q1 2023 | $35,800,941 | +12.7% | 147,779 | +35.1% | 0.00% | 0.0% |
| Q4 2022 | $31,759,157 | +727.5% | 109,420 | +85.3% | 0.00% | +300.0% |
| Q3 2022 | $3,838,000 | -35.4% | 59,064 | -28.8% | 0.00% | 0.0% |
| Q2 2022 | $5,939,000 | -38.2% | 82,953 | -15.4% | 0.00% | 0.0% |
| Q1 2022 | $9,617,000 | +134.7% | 98,024 | +102.8% | 0.00% | 0.0% |
| Q4 2021 | $4,097,000 | -24.7% | 48,338 | -29.1% | 0.00% | 0.0% |
| Q3 2021 | $5,438,000 | -40.4% | 68,168 | -27.2% | 0.00% | 0.0% |
| Q2 2021 | $9,126,000 | -70.3% | 93,677 | -64.4% | 0.00% | -80.0% |
| Q1 2021 | $30,751,000 | +436.3% | 262,898 | +409.6% | 0.01% | +400.0% |
| Q4 2020 | $5,734,000 | +72.1% | 51,587 | +83.8% | 0.00% | 0.0% |
| Q3 2020 | $3,332,000 | +10.4% | 28,060 | +5.3% | 0.00% | 0.0% |
| Q2 2020 | $3,018,000 | +82.6% | 26,654 | +7.6% | 0.00% | – |
| Q1 2020 | $1,653,000 | -23.3% | 24,774 | +4.7% | 0.00% | -100.0% |
| Q4 2019 | $2,156,000 | -28.5% | 23,664 | -32.4% | 0.00% | 0.0% |
| Q3 2019 | $3,017,000 | +98.4% | 34,983 | +141.2% | 0.00% | – |
| Q2 2019 | $1,521,000 | -9.7% | 14,504 | +7.9% | 0.00% | – |
| Q1 2019 | $1,684,000 | -76.7% | 13,440 | -79.0% | 0.00% | -100.0% |
| Q4 2018 | $7,212,000 | +55.3% | 63,979 | +195.1% | 0.00% | +100.0% |
| Q3 2018 | $4,643,000 | -30.2% | 21,683 | -8.8% | 0.00% | -50.0% |
| Q2 2018 | $6,649,000 | +363.0% | 23,772 | +93.3% | 0.00% | – |
| Q1 2018 | $1,436,000 | +54.7% | 12,300 | +21.6% | 0.00% | – |
| Q4 2017 | $928,000 | +263.9% | 10,117 | +79.2% | 0.00% | – |
| Q3 2017 | $255,000 | +304.8% | 5,646 | +43.7% | 0.00% | – |
| Q2 2017 | $63,000 | -4.5% | 3,928 | -9.6% | 0.00% | – |
| Q1 2017 | $66,000 | +560.0% | 4,344 | +554.2% | 0.00% | – |
| Q4 2016 | $10,000 | +233.3% | 664 | +165.6% | 0.00% | – |
| Q3 2016 | $3,000 | – | 250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |